1
|
Zheleznova AO, Sun J, Zhu SD, Kuzmenkova NV, Rozhkova AK, Petrov VG, Xing S, Shi K, Hou X, Kalmykov SN. Sorption behaviour of neptunium in marine and fresh water bottom sediments in Far East area of Russia (Lake Khanka and Amur Bay). J Environ Radioact 2024; 272:107334. [PMID: 38008046 DOI: 10.1016/j.jenvrad.2023.107334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/22/2023] [Revised: 11/12/2023] [Accepted: 11/14/2023] [Indexed: 11/28/2023]
Abstract
The concentration and sorption behavior of 237Np on the bottom sediments of water bodies in the Far East region of Russia (Lake Khanka and Peter the Great Bay) were studied for the first time. The 237Np concentrations vary from 1.06 × 10-6 to 4.43 × 10-5 mBq g-1 in the bottom sediments of Lake Khanka and from 1.05 × 10-4 to 2.52 × 10-3 mBq g-1 for Amur Bay. The experiment on the adsorption of Np on marine and lake sediment showed that it is sorbed through complexation with silicates (albite, leucite). The Np sorption isotherm on marine sediments is described by the Langmuir equation; the distribution coefficients (Kd) of Np vary from 57 to 588 mL g-1. For lake sediments, the isotherm is described by the Henry equation; the Kd value reaches 935 mL g-1.
Collapse
Affiliation(s)
- A O Zheleznova
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1 Bld.3, Moscow, Russia, 119991.
| | - J Sun
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China
| | - S D Zhu
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China
| | - N V Kuzmenkova
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1 Bld.3, Moscow, Russia, 119991; Institute of Geography, RAS, Staromonetny Per. 29, Bld. 4, Moscow, Russia
| | - A K Rozhkova
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1 Bld.3, Moscow, Russia, 119991; Vernadsky Institute of Geochemistry and Analytical Chemistry, RAS, St. Kosygin 19, Moscow, Russia, 119991
| | - V G Petrov
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1 Bld.3, Moscow, Russia, 119991
| | - S Xing
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China
| | - K Shi
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China
| | - X Hou
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China
| | - S N Kalmykov
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1 Bld.3, Moscow, Russia, 119991
| |
Collapse
|
2
|
Wang Y, Zhao G, Ma P, Jiang Y, Xing S, Wang S, Li N. Neoantigen-based therapeutic cancer vaccine: Towards a bright future. Pharmacol Res 2024; 199:107024. [PMID: 38042356 DOI: 10.1016/j.phrs.2023.107024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 11/29/2023] [Accepted: 11/29/2023] [Indexed: 12/04/2023]
Affiliation(s)
- Yuning Wang
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Guo Zhao
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Peiwen Ma
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Yale Jiang
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Shujun Xing
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Shuhang Wang
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
| | - Ning Li
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
| |
Collapse
|
3
|
Shen S, Xing S, Sang X, Yan B, Xie X, Fu B, Zhong C, Zhang S. Portrait stylized rendering for 3D light-field display based on radiation field and example guide. Opt Express 2023; 31:29664-29675. [PMID: 37710762 DOI: 10.1364/oe.494870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 08/07/2023] [Indexed: 09/16/2023]
Abstract
With the development of three-dimensional (3D) light-field display technology, 3D scenes with correct location information and depth information can be perceived without wearing any external device. Only 2D stylized portrait images can be generated with traditional portrait stylization methods and it is difficult to produce high-quality stylized portrait content for 3D light-field displays. 3D light-field displays require the generation of content with accurate depth and spatial information, which is not achievable with 2D images alone. New and innovative portrait stylization techniques methods should be presented to meet the requirements of 3D light-field displays. A portrait stylization method for 3D light-field displays is proposed, which maintain the consistency of dense views in light-field display when the 3D stylized portrait is generated. Example-based portrait stylization method is used to migrate the designated style image to the portrait image, which can prevent the loss of contour information in 3D light-field portraits. To minimize the diversity in color information and further constrain the contour details of portraits, the Laplacian loss function is introduced in the pre-trained deep learning model. The three-dimensional representation of the stylized portrait scene is reconstructed, and the stylized 3D light field image of the portrait is generated the mask guide based light-field coding method. Experimental results demonstrate the effectiveness of the proposed method, which can use the real portrait photos to generate high quality 3D light-field portrait content.
Collapse
|
4
|
Xing S, Qi XJ, Xia Y, Wu J, Fu WW. [Oligosarcoma: report of a case]. Zhonghua Bing Li Xue Za Zhi 2023; 52:850-852. [PMID: 37527994 DOI: 10.3760/cma.j.cn112151-20230111-00023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 08/03/2023]
Affiliation(s)
- S Xing
- Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao 266000, China
| | - X J Qi
- Department of Pathology, Linyi People's Hospital, Linyi 276000, China
| | - Y Xia
- Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao 266000, China
| | - J Wu
- Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao 266000, China
| | - W W Fu
- Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao 266000, China
| |
Collapse
|
5
|
Lee MM, Charalampidis EG, Xing S, Chong C, Kevrekidis PG. Breathers in lattices with alternating strain-hardening and strain-softening interactions. Phys Rev E 2023; 107:054208. [PMID: 37328995 DOI: 10.1103/physreve.107.054208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Accepted: 03/21/2023] [Indexed: 06/18/2023]
Abstract
This work focuses on the study of time-periodic solutions, including breathers, in a nonlinear lattice consisting of elements whose contacts alternate between strain hardening and strain softening. The existence, stability, and bifurcation structure of such solutions, as well as the system dynamics in the presence of damping and driving, are studied systematically. It is found that the linear resonant peaks in the system bend toward the frequency gap in the presence of nonlinearity. The time-periodic solutions that lie within the frequency gap compare well to Hamiltonian breathers if the damping and driving are small. In the Hamiltonian limit of the problem, we use a multiple scale analysis to derive a nonlinear Schrödinger equation to construct both acoustic and optical breathers. The latter compare very well with the numerically obtained breathers in the Hamiltonian limit.
Collapse
Affiliation(s)
- M M Lee
- Mathematics Department, California Polytechnic State University, San Luis Obispo, California 93407-0403, USA
| | - E G Charalampidis
- Mathematics Department, California Polytechnic State University, San Luis Obispo, California 93407-0403, USA
| | - S Xing
- Department of Mechanical Engineering, California Polytechnic State University, San Luis Obispo, California 93407-0403, USA
| | - C Chong
- Department of Mathematics, Bowdoin College, Brunswick, Maine 04011, USA
| | - P G Kevrekidis
- Department of Mathematics and Statistics, University of Massachusetts Amherst, Amherst, Massachusetts 01003-4515, USA
| |
Collapse
|
6
|
Huang H, Tang Y, Yu Y, Yu A, Wu D, Fang H, Wang S, Sun C, Wang X, Fan Q, Fang Y, Tang Q, Jiang N, Du J, Miao H, Bai Y, Ma P, Xing S, Cui D, Miao S, Jiang Y, Zhu J, Zhu Q, Leng Y, Guo LW, Liao S, Shao Y, Song Y, Liu Z, Hong M, Luo S, Xu B, Lan G, Li N. The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges. The Lancet Regional Health - Western Pacific 2023; 31:100624. [DOI: 10.1016/j.lanwpc.2022.100624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Revised: 09/20/2022] [Accepted: 10/13/2022] [Indexed: 11/19/2022]
|
7
|
Xing S, Sun HQ, Li MC. [Clinical characteristics and risk factors of periventricular-intraventricular hemorrhage in extremely low birth weight infants]. Zhonghua Yi Xue Za Zhi 2022; 102:3774-3778. [PMID: 36517428 DOI: 10.3760/cma.j.cn112137-20220616-01323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
Objective: To analyze the clinical characteristics and risk factors of periventricular-intraventricular hemorrhage (PIVH) in extremely low birth weight infants (ELBWI). Methods: From January 2019 to January 2022, the clinical data of 238 ELBWI admitted to the intensive care unit of Henan Provincial Children's Hospital within 1 week after birth and regular head color ultrasound examination were retrospective reviewed. The infants were divided into PIVH group and non-PIVH group according to whether PIVH occurred. The incidence and time of PIVH were described, and the differences in basic clinical features, perinatal conditions, postnatal treatment and complications between the two groups were compared. The risk factors of PIVH in ELBWI were further explored by multivariate binary logistic regression analysis. Results: Among 238 ELBWI (146 males and 92 females), 82 cases (34.5%) developed PIVH, including 28 cases (11.8%) of severe PIVH and 54 cases (22.7%) of mild PIVH. Among the 82 cases of PIVH, 68 cases occurred within 3 days after birth. Gestational age [(27.4±1.5) weeks vs (27.8±1.5) weeks, P=0.012], gestational diabetes mellitus [0 vs 9.0%(14/156), P=0.005], fibrinogen (FIB) [(1.8±0.5) g/L vs (2.7±0.9) g/L, P=0.012] were lower in PIVH group than in non-PIVH group. However, intrauterine distress [46.3%(38/82) vs 11.5%(18/156), P<0.001], birth asphyxia [85.4%(70/82) vs 62.8%(98/156), P<0.001], patent ductus arteriosus (PDA) [65.9%(54/82) vs 51.3%(80/156), P=0.017], failure to withdraw invasive ventilator within 1 week [82.9%(14/82) vs 67.3%(105/156), P=0.010], use of vasoactive drugs within 1 week [28.0%(23/82) vs 15.4%(24/156), P=0.020], acidosis [28.0%(23/82) vs 12.2%(19/156), P=0.002], and hemorrhagic disease [18.3%(15/82) vs 7.1%(11/156), P=0.008] were higher in PIVH group than in non-PIVH group. Multivariate binary logistic regression analysis found that the risk factors for PIVH in ELBWI were acidosis (OR=2.257, 95%CI: 1.104-4.614, P=0.026), use of vasoactive drugs within 1 week (OR=2.274, 95%CI: 1.148-4.504, P=0.018), bleeding disorders (OR=2.583, 95%CI: 1.075-6.206, P=0.034) use of vasoactive drugs within 1 week (OR=2.301, 95%CI: 1.153-4.591, P<0.001). Conclusions: The incidence of PIVH in ELBWI is high, which mostly occurs within 3 days after birth. Acidosis, hemorrhagic disease, use of vasoactive agents within 1 week and failure to evacuate invasive ventilators within 1 week may increase the risk of PIVH in ELBWI.
Collapse
Affiliation(s)
- S Xing
- Department of Neonatology, Children's Hospital affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou 450000, China
| | - H Q Sun
- Department of Neonatology, Children's Hospital affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou 450000, China
| | - M C Li
- Department of Neonatology, Children's Hospital affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou 450000, China
| |
Collapse
|
8
|
Guo X, Sang X, Yan B, Wang H, Ye X, Chen S, Wan H, Li N, Zeng Z, Chen D, Wang P, Xing S. Real-time dense-view imaging for three-dimensional light-field display based on image color calibration and self-supervised view synthesis. Opt Express 2022; 30:22260-22276. [PMID: 36224928 DOI: 10.1364/oe.461789] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Accepted: 05/26/2022] [Indexed: 06/16/2023]
Abstract
Three-Dimensional (3D) light-field display has achieved promising improvement in recent years. However, since the dense-view images cannot be collected fast in real-world 3D scenes, the real-time 3D light-field display is still challenging to achieve in real scenes, especially at the high-resolution 3D display. Here, a real-time 3D light-field display method with dense-view is proposed based on image color correction and self-supervised optical flow estimation, and a high-quality and high frame rate of 3D light-field display can be realized simultaneously. A sparse camera array is firstly used to capture sparse-view images in the proposed method. To eliminate the color deviation of the sparse views, the imaging process of the camera is analyzed, and a practical multi-layer perception (MLP) network is proposed to perform color calibration. Given sparse views with consistent color, the optical flow can be estimated by a lightweight convolutional neural network (CNN) at high speed, which uses the input image pairs to learn the optical flow in a self-supervised manner. With inverse warp operation, dense-view images can be synthesized in the end. Quantitative and qualitative experiments are performed to evaluate the feasibility of the proposed method. Experimental results show that over 60 dense-view images at a resolution of 1024 × 512 can be generated with 11 input views at a frame rate over 20 fps, which is 4× faster than previous optical flow estimation methods PWC-Net and LiteFlowNet3. Finally, large viewing angles and high-quality 3D light-field display at 3840 × 2160 resolution can be achieved in real-time.
Collapse
|
9
|
Chen Y, Sang X, Xing S, Guan Y, Zhang H, Wang K. Automatic co-design of light field display system based on simulated annealing algorithm and visual simulation. Opt Express 2022; 30:17577-17590. [PMID: 36221577 DOI: 10.1364/oe.457341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 04/26/2022] [Indexed: 06/16/2023]
Abstract
Accurate, fast, and reliable modeling and optimization methods play a crucial role in designing light field display (LFD) system. Here, an automatic co-design method of LFD system based on simulated annealing and visual simulation is proposed. The process of LFD content acquisition and optical reconstruction are modeled and simulated, the objective function for evaluating the display effect of the LFD system is established according to the simulation results. In case of maximum objective function, the simulated annealing optimization method is used to find the optimal parameters of the LFD system. The validity of the proposed method is confirmed through optical experiments.
Collapse
|
10
|
Wang S, Li Q, Ma P, Fang Y, Yu Y, Jiang N, Miao H, Tang Q, Yang Y, Xing S, Chen R, Yi X, Li N. KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients. Front Mol Biosci 2022; 9:831382. [PMID: 35359599 PMCID: PMC8962378 DOI: 10.3389/fmolb.2022.831382] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Accepted: 01/26/2022] [Indexed: 01/30/2023] Open
Abstract
KRAS is the most commonly mutated oncogene in human cancers. Targeted therapy and immunotherapy for this gene have made remarkable progress in recent years. However, comprehensive molecular landscape analysis of KRAS in rare tumors is lacking. Retrospective analysis was performed on clinical samples from patients with rare tumors collected between September 2015 and September 2021, using hybrid-capture-based next-generation sequencing for genomic profiling and immunohistochemistry assay for PD-L1. Of the 3,453 patients included in analysis, KRAS mutations were identified in 8.7% patients in overall; mutation rate and mutation subtypes varied widely across tumor systems and subtypes. KRAS mutations included 21 missense mutations, of which G12D (29.2%), G12V (24.6%), and G13D (10.8%) were most common. Interestingly, KRAS G12C was observed in 0.6% patients overall, and in 5.7% of sarcomatoid carcinoma of the lung and 5.4% of clear cell ovarian cancer tumors, but none in small-bowel cancer tumors. 31.8% KRAS mutations and 36.4% KRAS G12C mutations co-occurred with other targetable alterations. No significant correlation was observed between TMB-H, MSI-H, PD-L1 status, and KRAS mutation status, which may be related to the high proportion of G12D. This study is the first KRAS mutation landscape study in rare tumors of large sample size in China and worldwide. Our results suggest that targeted therapy and immunotherapy are both feasible, albeit complex, in these patients. This information may have significant impact on the operation of clinical trials for rare tumor patients with KRAS mutations in China.
Collapse
Affiliation(s)
- Shuhang Wang
- Clinical Cancer Centre, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Qin Li
- Geneplus-Beijing Institute, Beijing, China
| | - Peiwen Ma
- Clinical Cancer Centre, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yuan Fang
- Clinical Cancer Centre, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yue Yu
- Clinical Cancer Centre, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Ning Jiang
- Clinical Cancer Centre, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Huilei Miao
- Clinical Cancer Centre, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Qiyu Tang
- Clinical Cancer Centre, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yuqi Yang
- NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People’s Hospital, Guiyang, China
| | - Shujun Xing
- Clinical Cancer Centre, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | | | - Xin Yi
- Geneplus-Beijing Institute, Beijing, China
- *Correspondence: Xin Yi, ; Ning Li,
| | - Ning Li
- Clinical Cancer Centre, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- *Correspondence: Xin Yi, ; Ning Li,
| |
Collapse
|
11
|
Guo X, Sang X, Chen D, Wang P, Wang H, Liu X, Li Y, Xing S, Yan B. Real-time optical reconstruction for a three-dimensional light-field display based on path-tracing and CNN super-resolution. Opt Express 2021; 29:37862-37876. [PMID: 34808851 DOI: 10.1364/oe.441714] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Accepted: 10/21/2021] [Indexed: 06/13/2023]
Abstract
Three-Dimensional (3D) light-field display plays a vital role in realizing 3D display. However, the real-time high quality 3D light-field display is difficult, because super high-resolution 3D light field images are hard to be achieved in real-time. Although extensive research has been carried out on fast 3D light-field image generation, no single study exists to satisfy real-time 3D image generation and display with super high-resolution such as 7680×4320. To fulfill real-time 3D light-field display with super high-resolution, a two-stage 3D image generation method based on path tracing and image super-resolution (SR) is proposed, which takes less time to render 3D images than previous methods. In the first stage, path tracing is used to generate low-resolution 3D images with sparse views based on Monte-Carlo integration. In the second stage, a lite SR algorithm based on a generative adversarial network (GAN) is presented to up-sample the low-resolution 3D images to high-resolution 3D images of dense views with photo-realistic image quality. To implement the second stage efficiently and effectively, the elemental images (EIs) are super-resolved individually for better image quality and geometry accuracy, and a foreground selection scheme based on ray casting is developed to improve the rendering performance. Finally, the output EIs from CNN are used to recompose the high-resolution 3D images. Experimental results demonstrate that real-time 3D light-field display over 30fps at 8K resolution can be realized, while the structural similarity (SSIM) can be over 0.90. It is hoped that the proposed method will contribute to the field of real-time 3D light-field display.
Collapse
|
12
|
Xing S, Pursley J, Shin J, Alfonso C, Domal S, Withrow J, Bolch W, Grassberger C, Paganetti H. Dynamic Hepatic Blood Flow Model Shows Greater Impact of Total Treatment Time Than Integral Dose for Assessing Dose to Circulating Lymphocytes. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Wang S, Chen K, Lei Q, Ma P, Yuan AQ, Zhao Y, Jiang Y, Fang H, Xing S, Fang Y, Jiang N, Miao H, Zhang M, Sun S, Yu Z, Tao W, Zhu Q, Nie Y, Li N. The state of the art of bispecific antibodies for treating human malignancies. EMBO Mol Med 2021; 13:e14291. [PMID: 34431224 PMCID: PMC8422067 DOI: 10.15252/emmm.202114291] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 07/08/2021] [Accepted: 07/09/2021] [Indexed: 12/26/2022] Open
Abstract
Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been extensively explored in translational and clinical studies since they were first developed in the 1960s. Many bsAbs are being tested in clinical trials for treating a variety of diseases, mostly cancer. Here, we provide an overview of various types of bsAbs in clinical studies and discuss their targets, safety profiles, and efficacy. We also highlight the current challenges, potential solutions, and future directions of bsAb development for cancer treatment.
Collapse
Affiliation(s)
- Shuhang Wang
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
| | - Kun Chen
- NHC Key Laboratory of Pulmonary Immunological Diseases is supported by the non‐profit Central Research Institute fund of Chinese Academy of Medical Sciences (2019PT320003)Guizhou Provincial People’s HospitalGuiyangChina
| | - Qi Lei
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
| | - Peiwen Ma
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
| | | | - Yong Zhao
- Nanjing Umab‐biopharma Co., LtdNanjingChina
| | | | - Hong Fang
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
| | - Shujun Xing
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
| | - Yuan Fang
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
| | - Ning Jiang
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
| | - Huilei Miao
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
| | - Minghui Zhang
- Department of Medical OncologyHarbin Medical University Cancer HospitalHarbinChina
| | - Shujun Sun
- Queen Mary SchoolNanchang UniversityNanchangChina
| | | | - Wei Tao
- China Pharmaceutical UniversityNanjingChina
| | - Qi Zhu
- China Pharmaceutical UniversityNanjingChina
| | - Yingjie Nie
- NHC Key Laboratory of Pulmonary Immunological Diseases is supported by the non‐profit Central Research Institute fund of Chinese Academy of Medical Sciences (2019PT320003)Guizhou Provincial People’s HospitalGuiyangChina
| | - Ning Li
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
| |
Collapse
|
14
|
Xing S, Ma Y, Rong L. P-260 Plasma exRNA-based identification of novel biomarkers in early gastric cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
15
|
Wang S, Sun J, Chen K, Ma P, Lei Q, Xing S, Cao Z, Sun S, Yu Z, Liu Y, Li N. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. BMC Med 2021; 19:140. [PMID: 34112147 PMCID: PMC8194199 DOI: 10.1186/s12916-021-02006-4] [Citation(s) in RCA: 57] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Accepted: 05/13/2021] [Indexed: 12/26/2022] Open
Abstract
Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to treat patients. Its diverse TCR clonality, superior tumor-homing ability, and low off-target toxicity endow TIL therapy unique advantages in treating solid tumors compared with other adoptive cellular therapies. Nevertheless, the successful application of TIL therapy currently is still limited to several types of tumors. Herein in this review, we summarize the fundamental work in the field of TIL therapy and the current landscape and advances of TIL clinical trials worldwide. Moreover, the limitations of the current TIL regimen have been discussed and the opportunities and challenges in the development of next-generation TIL are highlighted. Finally, the future directions of TIL therapy towards a broader clinical application have been proposed.
Collapse
Affiliation(s)
- Shuhang Wang
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | | | - Kun Chen
- NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang, China
| | - Peiwen Ma
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Qi Lei
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Shujun Xing
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | | | - Shujun Sun
- Queen Mary School, Nanchang University, Nanchang, 330006, China
| | | | - Yarong Liu
- Grit Biotechnology Ltd., Shanghai, China.
| | - Ning Li
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
| |
Collapse
|
16
|
Wang S, Huang HY, Wu D, Fang H, Ying J, Bai Y, Yu Y, Fang Y, Jiang N, Sun C, Yu A, Fan Q, Xing S, Ni Y, Zhang W, Wu C, Ji X, Wang H, Guo Y, Tang Q, Wang Y, Tang Y, Li N. Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours. BMJ Open 2021; 11:e044543. [PMID: 34083331 PMCID: PMC8183209 DOI: 10.1136/bmjopen-2020-044543] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Accepted: 05/16/2021] [Indexed: 12/02/2022] Open
Abstract
INTRODUCTION Limited clinical studies have been conducted on rare solid tumours, and there are few guidelines on the diagnosis and treatment, including experiences with targeted therapy and immunotherapy, of rare solid tumours in China, resulting in limited treatment options and poor outcomes. This study first proposes a definition of rare tumours and is designed to test the preliminary efficacy of targeted and immunotherapy drugs for the treatment of rare tumours. METHODS AND ANALYSIS This is a phase II, open-label, non-randomised, multiarm, single-centre clinical trial in patients with advanced rare solid tumours who failed standard treatment; the study aims to evaluate the safety and efficacy of targeted drugs in patients with advanced rare solid tumours with corresponding actionable alterations, as well as the safety and efficacy of immune checkpoint (programmed death receptor inhibitor 1, PD-1) inhibitors in patients with advanced rare solid tumours without actionable alterations. Patients with advanced rare tumours who fail standardised treatment and carry actionable alterations (Epidermal growth factor receptor (EGFR) mutations, ALK gene fusions, ROS-1 gene fusions, C-MET gene amplifications/mutations, BRAF mutations, CDKN2A mutations, BRCA1/2 mutations, HER-2 mutations/overexpressions/amplifications or C-KIT mutations) will be enrolled in the targeted therapy arm and be given the corresponding targeted drugs. Patients without actionable alterations will be enrolled in the PD-1 inhibitor arm and be treated with sintilimab. After the patients treated with vemurafenib, niraparib and palbociclib acquire resistance, they will receive combination treatment with sintilimab or atezolizumab. With the use of Simon's two-stage Minimax design, and the sample size was estimated to be 770. The primary endpoint of this study is the objective response rate. The secondary endpoints are progression-free survival in the targeted treatment group and single-agent immunotherapy group; the duration of response in the targeted therapy and single-agent immunotherapy groups; durable clinical benefit in the single-agent immunotherapy group; and the incidence of adverse events. ETHICS AND DISSEMINATION Ethics approval was obtained from the Chinese Academy of Medical Sciences (ID: 20/132-2328). The results from this study will be actively disseminated through manuscript publications and conference presentations. TRIAL REGISTRATION NUMBERS NCT04423185; ChiCTR2000039310.
Collapse
Affiliation(s)
- Shuhang Wang
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Hui-Yao Huang
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Dawei Wu
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Hong Fang
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Jianming Ying
- Pathology Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Ying Bai
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Yue Yu
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Yuan Fang
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Ning Jiang
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Chao Sun
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Anqi Yu
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Qi Fan
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Shujun Xing
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Yufen Ni
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Wei Zhang
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Chenhua Wu
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Xinqian Ji
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Hui Wang
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Yaqian Guo
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Qiyu Tang
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Yuan Wang
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Yu Tang
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| | - Ning Li
- Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China
| |
Collapse
|
17
|
Wang S, Fang Y, Jiang N, Xing S, Li Q, Chen R, Yi X, Zhang Z, Li N. Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy. Front Immunol 2021; 12:631483. [PMID: 33732253 PMCID: PMC7959707 DOI: 10.3389/fimmu.2021.631483] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Accepted: 01/18/2021] [Indexed: 01/10/2023] Open
Abstract
Treatment options for rare tumors are limited, and comprehensive genomic profiling may provide useful information for novel treatment strategies and improving outcomes. The aim of this study is to explore the treatment opportunities of patients with rare tumors using immune checkpoint inhibitors (ICIs) that have already been approved for routine treatment of common tumors. We collected immunotherapy-related indicators data from a total of 852 rare tumor patients from across China, including 136 programmed cell death ligand-1 (PD-L1) expression, 821 tumors mutational burden (TMB), 705 microsatellite instability (MSI) and 355 human leukocyte antigen class I (HLA-I) heterozygosity reports. We calculated the positive rates of these indicators and analyzed the consistency relationship between TMB and PD-L1, TMB and MSI, and HLA-I and PD-L1. The prevalence of PD-L1 positive, TMB-H, MSI-, and HLA-I -heterozygous was 47.8%, 15.5%, 7.4%, and 78.9%, respectively. The consistency ratio of TMB and PD-L1, TMB and MSI, and HLA-I and PD-L1 was 54.8% (78/135), 87.3% (598/685), and 47.4% (54/114), respectively. The prevalence of the four indicators varied widely across tumors systems and subtypes. The probability that neuroendocrine tumors (NETs) and biliary tumors may benefit from immunotherapy is high, since the proportion of TMB-H is as high as 50% and 25.4% respectively. The rates of PD-L1 positivity, TMB-H and MSI-H in carcinoma of unknown primary (CUP) were relatively high, while the rates of TMB-H and MSI-H in soft tissue tumors were both relatively low. Our study revealed the distribution of immunotherapeutic indicators in patients with rare tumors in China. Comprehensive genomic profiling may offer novel therapeutic modalities for patients with rare tumors to solve the dilemma of limited treatment options.
Collapse
Affiliation(s)
- Shuhang Wang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cell Biology, Peking University Cancer Hospital and Institute, Beijing, China
| | - Yuan Fang
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Ning Jiang
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Shujun Xing
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Qin Li
- Department of Medical Center, Geneplus-Beijing Institute, Beijing, China
| | - Rongrong Chen
- Department of Medical Center, Geneplus-Beijing Institute, Beijing, China
| | - Xin Yi
- Department of Medical Center, Geneplus-Beijing Institute, Beijing, China
| | - Zhiqian Zhang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cell Biology, Peking University Cancer Hospital and Institute, Beijing, China
| | - Ning Li
- Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
18
|
Wang S, Sun F, Huang H, Chen K, Li QJ, Zhang L, Wang E, Wang C, Zhang H, Yuan AQ, Chen B, Deng T, Liu Y, Sun J, Liu D, Yu Y, Fang Y, Jiang N, Wu D, Fang H, Bai Y, Xing S, Ni Y, Fan Q, Yu A, Sun C, Tang Y, Li N, Xu B, He J. The Landscape of Cell and Gene Therapies for Solid Tumors. Cancer Cell 2021; 39:7-8. [PMID: 33434513 DOI: 10.1016/j.ccell.2020.12.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Shuhang Wang
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Fa Sun
- Guizhou Provincial People's Hospital, Guiyang, China
| | - Huiyao Huang
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Kun Chen
- Guizhou Provincial People's Hospital, Guiyang, China
| | - Qi-Jing Li
- Department of Immunology, Duke University Medical Center, Durham, NC, USA
| | - Lu Zhang
- TCRCure Biopharma Ltd., Durham, NC, USA
| | - Enxiu Wang
- Naning CART Medical Technology Ltd, Naning, Jiangsu, China & YouJiang Medical University for Nationalities
| | - Chen Wang
- Naning CART Medical Technology Ltd, Naning, Jiangsu, China & YouJiang Medical University for Nationalities
| | - Hai Zhang
- Naning CART Medical Technology Ltd, Naning, Jiangsu, China & YouJiang Medical University for Nationalities
| | | | | | - Tao Deng
- Chengdu MedGenCell Co. Ltd., Chengdu, Sichuan, China
| | - Yarong Liu
- Grit Biotechnology Ltd., Shanghai, China
| | | | - Dongfang Liu
- Department of Pathology, Immunology and Laboratory Medicine, Center for Immunity and Inflammation, Rutgers-New Jersey Medical School, Newark, NJ, USA
| | - Yue Yu
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yuan Fang
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Ning Jiang
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Dawei Wu
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Hong Fang
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Ying Bai
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Shujun Xing
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yufen Ni
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Qi Fan
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Anqi Yu
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Chao Sun
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yu Tang
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Ning Li
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
| | - Binghe Xu
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Jie He
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
19
|
Guan Y, Sang X, Xing S, Chen Y, Li Y, Chen D, Yu X, Yan B. Parallel multi-view polygon rasterization for 3D light field display. Opt Express 2020; 28:34406-34421. [PMID: 33182911 DOI: 10.1364/oe.408857] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Accepted: 10/19/2020] [Indexed: 06/11/2023]
Abstract
Three-dimensional (3D) light field displays require samples of image data captured from a large number of regularly spaced camera images to produce a 3D image. Generally, it is inefficient to generate these images sequentially because a large number of rendering operations are repeated in different viewpoints. The current 3D image generation algorithm with traditional single viewpoint computer graphics techniques is not sufficiently well suited to the task of generating images for the light field displays. A highly parallel multi-view polygon rasterization (PMR) algorithm for 3D multi-view image generation is presented. Based on the coherence of the triangular rasterization calculation among different viewpoints, the related rasterization algorithms including primitive setup, plane function, and barycentric coordinate interpolation in the screen space are derived. To verify the proposed algorithm, a hierarchical soft rendering pipeline with GPU is designed and implemented. Several groups of images of 3D objects are used to verify the performance of the PMR method, and the correct 3D light field image can be achieved in real time.
Collapse
|
20
|
Ma W, Li L, Xing S. PGE2/EP4 receptor and TRPV1 channel are involved in repeated restraint stress-induced prolongation of sensitization pain evoked by subsequent PGE2 challenge. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Guan Y, Sang X, Xing S, Li Y, Chen Y, Chen D, Yang L, Yan B. Backward ray tracing based high-speed visual simulation for light field display and experimental verification. Opt Express 2019; 27:29309-29318. [PMID: 31684667 DOI: 10.1364/oe.27.029309] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Accepted: 09/18/2019] [Indexed: 06/10/2023]
Abstract
The exiting simulation method is not capable of achieving three-dimensional (3D) display result of the light field display (LFD) directly, which is important for design and optimization. Here, a high-speed visual simulation method to calculate the 3D image light field distribution is presented. Based on the backward ray tracing technique (BRT), the geometric and optical models of the LFD are constructed. The display result images are obtained, and the field of view angle (FOV) and depth of field (DOF) can be estimated, which are consistent with theoretical results and experimental results. The simulation time is 1s when the number of sampling rays is 3840×2160×100, and the computational speed of the method is at least 1000 times faster than that of the traditional physics-based renderer. A prototype was fabricated to evaluate the feasibility of the proposed method. From the results, our simulation method shows good potential for predicting the displayed image of the LFD for various positions of the observer's eye with sufficient calculation speed.
Collapse
|
22
|
Li Y, Sang X, Xing S, Guan Y, Yang S, Chen D, Yang L, Yan B. Real-time optical 3D reconstruction based on Monte Carlo integration and recurrent CNNs denoising with the 3D light field display. Opt Express 2019; 27:22198-22208. [PMID: 31510515 DOI: 10.1364/oe.27.022198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/01/2019] [Accepted: 06/20/2019] [Indexed: 06/10/2023]
Abstract
A general integral imaging generation method based on the path-traced Monte Carlo (MC) method and recurrent convolutional neural networks denoising is presented. According to the optical layer structure of the three-dimensional (3D) light field display, screen pixels are encoded to specific viewpoints, then the directional rays are cast from viewpoints to screen pixels to preform the path integral. In the process of the integral, advanced illumination is used for high-quality elemental image array (EIA) generation. Recurrent convolutional neural networks are implemented as an auxiliary post-processing for the EIA to eliminate the noise of the 3D image in MC integration. 4K (3840 × 2160) resolution, 2 sample/pixel and the ray path tracing method are realized in the experiment. Experimental results demonstrate that the structural similarity metric (SSIM) value and peak signal-to-noise ratio (PSNR) gain of the reconstructed 3D image and target 3D image exceed 90% and 10 dB within 10 frames, respectively. Besides, real-time frame rate is more than 30 fps, showing the super efficiency and quality in optical 3D reconstruction.
Collapse
|
23
|
Li Y, Xing S, Chen R, Zhou Z, Guo Y. The effect of oral polyethylene glycol combined with simethicone for colonoscopy on cecal intubation rate, tolerability and acceptability : a systematic review and meta-analysis. Acta Gastroenterol Belg 2019; 82:407-415. [PMID: 31566329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
OBJECTIVE To assess the efficacy adjunction of oral simethicone to polyethylene glycol as bowel preparation agent on cecal intubation rate. METHODS We searched EMBASE, PubMed and Cochrane library for randomized controlled trials regarding simeticone plus polyethylene glycol as oral drinking agents before gastroscopy,we used the soft RevMan5.3 to perform statistical analysis and stata12.0 for publication bias. RESULTS 12 randomized trials that met the inclusion criteria were therefore pooled into a meta-analysis, which included a total of 5,112 patients. There were no significant differences on cecal intubation rate in two groups(RR=1.0,95%CI : 0.99-1.01, P=0.93) with moderate level of evidence;Subgroups analysis of 2LPEG+ Simethicone VS 2LPEG(RR =1.0, 95% CI : 0.98,1.01), 2LPEG+ Simethicone VS 4L PEG (RR=1.00, 95% CI : 0.98,1.02), PEG+ Simethicone with bisacodyl vs PEG (RR =1.00, 95% CI : 0.99,1.02), PEG+Simethicone without bisacodyl vs PEG (RR =1.00, 95% CI : 0.98,1.02) showed no difference on cecal intubation rate.There was aslo no significant difference on cecal intubation time.Abdominal bloating incidence was lower in PEG+Simethicone group than that in PEG group (RR=0.53, 95%CI : 0.31, 0.91, P=0.02). The meta-analysis result also showed a better acceptability in PEG+Simethicone group (RR=1.28, 95% CI : 1.01, 1.49, P=0.001). CONCLUSION Adjunction of oral simethicone to polyethylene glycol as bowel preparation agent dose not improve cecal intubation rate on colonoscopy,but with better gastrointestinal tolerability and acceptability.
Collapse
Affiliation(s)
- Y Li
- Department of Gastroenterology, Xiantao first People's Hospital, Xiantao City, China
| | - S Xing
- Department of Gastroenterology, Liaocheng Second People's Hospital, Liaocheng City, China
| | - R Chen
- Department of Gastroenterology, Xiantao first People's Hospital, Xiantao City, China
| | - Z Zhou
- Department of Gastroenterology, Xiantao first People's Hospital, Xiantao City, China
| | - Y Guo
- Department of Evidence-Based Medicine and Clinical Epidemiology, Zhongnan Hospital of Wuhan University, Wuhan, China
| |
Collapse
|
24
|
Liu G, Tan S, Peng K, Dang C, Xing S, Xie C, Zeng J. Network change in the ipsilesional cerebellum is correlated with motor recovery following unilateral pontine infarction. Eur J Neurol 2019; 26:1266-1273. [PMID: 31021033 DOI: 10.1111/ene.13974] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2018] [Accepted: 04/23/2019] [Indexed: 10/27/2022]
Affiliation(s)
- G. Liu
- Department of Neurology and Stroke Center The First Affiliated Hospital Sun Yat‐Sen University GuangzhouChina
| | - S. Tan
- Department of Neurology and Stroke Center The First Affiliated Hospital Sun Yat‐Sen University GuangzhouChina
| | - K. Peng
- Department of Medical Imaging State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Sun Yat‐Sen University Cancer Center Guangzhou China
| | - C. Dang
- Department of Neurology and Stroke Center The First Affiliated Hospital Sun Yat‐Sen University GuangzhouChina
| | - S. Xing
- Department of Neurology and Stroke Center The First Affiliated Hospital Sun Yat‐Sen University GuangzhouChina
| | - C. Xie
- Department of Medical Imaging State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Sun Yat‐Sen University Cancer Center Guangzhou China
| | - J. Zeng
- Department of Neurology and Stroke Center The First Affiliated Hospital Sun Yat‐Sen University GuangzhouChina
| |
Collapse
|
25
|
Liu Z, Huang Z, Yang W, Li Z, Xing S, Li H, Hu B, Li P. Expression of orphan GPR56 correlates with tumor progression in human epithelial ovarian cancer. Neoplasma 2019; 64:32-39. [PMID: 27881002 DOI: 10.4149/neo_2017_104] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
G protein-coupled receptor 56 (GPR56) has been demonstrated to be a significant prognostic predictor in several types of malignances, including melanoma, glioblastoma, breast cancer, colon cancer, and pancreatic cancer. GPR56 has a putative mucin-like extracellular domain, indicating functions for this receptor in the cell-cell interactions and triggering different downstream signaling pathways responsible for regulating cell survival, proliferation, adhesion, and migration. But the expression and clinical significance of GPR56 has not been elucidated in epithelial ovarian cancer (EOC). We detected GPR56 expression by immunohistochemistry in 110 samples of ovarian serous carcinoma to explore the correlation between its expression and clinicopathologic characteristics and overall survival. As the result, we found that GPR56 expression is significantly associated with advanced FIGO stage (P = 0.01) and positive lymph node invasion (P = 0.016), and it serves as an independent unfavorable prognostic factor through univariate and multivariate analysis. GPR56 knockdown could dramatically decrease the proliferation and invasion of epithelial ovarian cancer cells through down-regulating the RhoA-GTP level and up-regulating the E-cadherin level, which indicates GPR56 could promote the progression and invasion of EOC. In conclusion, GPR56 expression was demonstrated as an independent prognostic factor in EOC, suggesting that GPR56 may play an oncogenic role through the Rho and E-cadherin pathway and GPR56 could be a novel potential drug target in EOC.
Collapse
|
26
|
Xing S, Zhang X, Liu JH, Huang X, Zhou P. Host MyD88 signaling protects against acute graft-versus-host disease after allogeneic bone marrow transplantation. Clin Exp Immunol 2018; 195:121-131. [PMID: 30317551 DOI: 10.1111/cei.13215] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2018] [Revised: 08/05/2018] [Accepted: 09/02/2018] [Indexed: 11/26/2022] Open
Abstract
Recent experimental strategies to reduce graft-versus-host disease (GVHD) have focused largely on modifying innate immunity. Toll-like receptor (TLR)-driven myeloid differentiation primary response 88 (MyD88)-dependent signalling pathways that initiate adaptive immune function are also critical for the pathogenesis of GVHD. This study aimed to delineate the role of host MyD88 in the development of acute GVHD following fully major histocompatibility complex-mismatched allogeneic bone marrow transplantation (BMT). When myeloablated BALB/c MyD88 knock-out recipients were transplanted with C57BL/6 (B6) donor cells, they developed significantly more severe GVHD than wild-type (WT) BALB/c hosts. The increased morbidity and mortality in MyD88-/- mice correlated with increased serum levels of lipopolysaccharide and elevated inflammatory cytokines in GVHD target organs. Additionally, MyD88 deficiency in BMT recipients led to increased donor T cell expansion and more donor CD11c+ cell intestinal infiltration with apoptotic cells but reduced proliferation of intestinal epithelial cells compared with that in WT BMT recipients. Decreased expression of tight junction mRNA in epithelial cells of MyD88-/- mice suggested that MyD88 contributes to intestinal integrity. Cox-2 expression in the GVHD-targeted organs of WT mice is increased upon GVHD induction, but this enhanced expression was obviously inhibited by MyD88 deficiency. The present findings demonstrate an unexpected role for host MyD88 in preventing GVHD after allogeneic BMT.
Collapse
Affiliation(s)
- S Xing
- Department of Gastroenterology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.,Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Key Laboratory of Organ Transplantation, Ministry of Health and Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, China
| | - X Zhang
- Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Key Laboratory of Organ Transplantation, Ministry of Health and Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, China.,Department of Breast Surgery, Renmin hospital of Wuhan University, Wuhan University, Wuhan, China
| | - J H Liu
- Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Key Laboratory of Organ Transplantation, Ministry of Health and Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, China
| | - X Huang
- Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Key Laboratory of Organ Transplantation, Ministry of Health and Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, China
| | - P Zhou
- Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Key Laboratory of Organ Transplantation, Ministry of Health and Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, China
| |
Collapse
|
27
|
Sang X, Gao X, Yu X, Xing S, Li Y, Wu Y. Interactive floating full-parallax digital three-dimensional light-field display based on wavefront recomposing. Opt Express 2018; 26:8883-8889. [PMID: 29715849 DOI: 10.1364/oe.26.008883] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/12/2018] [Accepted: 03/21/2018] [Indexed: 06/08/2023]
Abstract
Advanced three-dimensional (3D) imaging techniques can acquire high-resolution 3D biomedical and biological data, but available digital display methods show this data in restricted two dimensions. 3D light-field displays optically reconstruct realistic 3D image by carefully tailoring light fields, and a natural and comfortable 3D sense of real objects or scenes is expected. An interactive floating full-parallax 3D light-field display with all depth cues is demonstrated with 3D biomedical and biological data, which are capable of achieving high efficiency and high image quality. A compound lens-array with two pieces of lens in each lens unit is designed and fabricated to suppress the aberrations and increase the viewing angle. The optimally designed holographic functional screen is used to recompose the light distribution from the lens-array. The imaging distortion can be decreased to less than 1.9% from more than 20%. The real time interactive floating full-parallax 3D light-field image with the clear displayed depth of 30 cm can be perceived with the right geometric occlusion and smooth parallax in the viewing angle of 45°, where 9216 viewpoints are used.
Collapse
|
28
|
Liu Y, Zhang YY, Kou QW, Chen Y, Han DL, Wang DD, Lu ZY, Chen L, Yang JH, Xing S. Eco-friendly seeded Fe3O4-Ag nanocrystals: a new type of highly efficient and low cost catalyst for methylene blue reduction. RSC Adv 2018; 8:2209-2218. [PMID: 35542618 PMCID: PMC9077205 DOI: 10.1039/c7ra11348j] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2017] [Accepted: 01/03/2018] [Indexed: 12/17/2022] Open
Abstract
Hybrid Fe3O4-Ag nanocrystals, a new type of highly efficient and reusable catalyst for methylene blue (MB) reduction, are fabricated by a novel seed deposition process. X-ray diffraction and Mössbauer spectroscopy results show that the developed iron oxides are in a pure magnetite Fe3O4 phase. Upon manipulating the amount of Ag seeds capsuled on the modified surfaces of Fe3O4 nanocrystals, the catalytic capacities on the reduction of MB can be precisely adjusted with a tunable fabrication cost control. The linear correlation of the reduced MB concentration versus reaction time catalyzed by our developed hybrid Fe3O4-Ag nanocrystals is coherent with pseudo first order kinetics. Importantly, with remarkable recyclability features, the hybrid Fe3O4-Ag nanocrystals can be easily separated by applying an external magnetic field. The tailored catalytic performances of the hybrid Fe3O4-Ag nanocrystals during MB reduction are attributed to the optimized dynamic electron transfer process, which dominates the electrochemical mechanism wherein the nucleophilic BH4− ions donate electrons to electrophilic organic MB through Ag seeds in a regulated amount. Such developed hybrid Fe3O4-Ag nanocrystals pave the way towards the mass production of highly efficient and low cost catalysts for methylene blue reduction. Hybrid Fe3O4-Ag nanocrystals, a new type of highly efficient and reusable catalyst for methylene blue (MB) reduction, are fabricated by a novel seed deposition process.![]()
Collapse
Affiliation(s)
- Y. Liu
- College of Physics
- Jilin Normal University
- Siping 136000
- China
- Key Laboratory of Functional Materials Physics and Chemistry of the Ministry of Education
| | - Y. Y. Zhang
- College of Physics
- Jilin Normal University
- Siping 136000
- China
- Key Laboratory of Functional Materials Physics and Chemistry of the Ministry of Education
| | - Q. W. Kou
- College of Physics
- Jilin Normal University
- Siping 136000
- China
- Key Laboratory of Functional Materials Physics and Chemistry of the Ministry of Education
| | - Y. Chen
- College of Physics
- Jilin Normal University
- Siping 136000
- China
- Key Laboratory of Functional Materials Physics and Chemistry of the Ministry of Education
| | - D. L. Han
- School of Materials Science and Engineering
- Changchun University of Science and Technology
- Changchun 130022
- China
| | - D. D. Wang
- Technology Development Department
- GLOBALFOUNDRIES (Singapore) Pte. Ltd
- Singapore 738406
- Singapore
| | - Z. Y. Lu
- School of Environment and Safety Engineering
- Jiangsu University
- Zhenjiang 212013
- China
| | - L. Chen
- College of Physics
- Jilin Normal University
- Siping 136000
- China
- Key Laboratory of Functional Materials Physics and Chemistry of the Ministry of Education
| | - J. H. Yang
- College of Physics
- Jilin Normal University
- Siping 136000
- China
- Key Laboratory of Functional Materials Physics and Chemistry of the Ministry of Education
| | - S. Xing
- United Microelect Corp. Ltd
- Singapore 519528
- Singapore
| |
Collapse
|
29
|
Affiliation(s)
- S Xing
- Respiratory Department, The Central Hospital of Linyi, Linyi, China
| | - Y Zhu
- Respiratory Department, The Central Hospital of Linyi, Linyi, China
| | - Y Sun
- Chest Surgery Department, The Central Hospital of Linyi, Linyi, China
| |
Collapse
|
30
|
Xing S, Sharp LK, Touchette DR. Weight loss drugs and lifestyle modification: Perceptions among a diverse adult sample. Patient Educ Couns 2017; 100:592-597. [PMID: 27847132 DOI: 10.1016/j.pec.2016.11.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Revised: 09/26/2016] [Accepted: 11/08/2016] [Indexed: 06/06/2023]
Abstract
OBJECTIVES Explore how adults from diverse racial and socioeconomic backgrounds perceive the use of weight loss drugs (prescription, over-the counter, herbals and supplements) and lifestyle modification. METHODS Individual, face-to-face, semi-structured interviews were conducted with persons presenting to an academic hospital-affiliated outpatient pharmacy serving ethnic minorities and low income individuals. RESULTS Fifty persons were interviewed, including 21 African Americans, 11 Hispanics and 17 low-income individuals (annual income <$20,000), of whom 33 self-reported as overweight or obese. Ever-users (14/50) and nonusers (36/50) of weight loss drugs expressed a belief in the importance of diet and exercise, but were not necessarily doing so themselves. Fear of side effects and skepticism towards efficacy of drugs deterred use. Some expressed concern over herbal product safety; others perceived herbals as natural and safe. Drugs were often viewed as a short-cut and not a long-term weight management solution. CONCLUSION A range of concerns related to the safety and efficacy of weight loss drugs were expressed by this lower income, ethnically diverse population of underweight to obese adults. PRACTICE IMPLICATIONS There is need and opportunity for healthcare providers to provide weight loss advice and accurate information regarding the safety and efficacy of various types of weight loss approaches.
Collapse
Affiliation(s)
- S Xing
- University of Illinois at Chicago Department of Pharmacy Systems, Outcomes and Policy, Chicago, IL, 833 South Wood St (MC 871), 60612-7230, USA.
| | - L K Sharp
- University of Illinois at Chicago Department of Pharmacy Systems, Outcomes and Policy, Chicago, IL, 833 South Wood St (MC 871), 60612-7230, USA.
| | - D R Touchette
- University of Illinois at Chicago Department of Pharmacy Systems, Outcomes and Policy, Chicago, IL, 833 South Wood St (MC 871), 60612-7230, USA.
| |
Collapse
|
31
|
Xing S, Sang X, Yu X, Duo C, Pang B, Gao X, Yang S, Guan Y, Yan B, Yuan J, Wang K. High-efficient computer-generated integral imaging based on the backward ray-tracing technique and optical reconstruction. Opt Express 2017; 25:330-338. [PMID: 28085827 DOI: 10.1364/oe.25.000330] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
A high-efficient computer-generated integral imaging (CGII) method is presented based on the backward ray-tracing technique. In traditional CGII methods, the total rendering time is long, because a large number of cameras are established in the virtual world. The ray origin and the ray direction for every pixel in elemental image array are calculated with the backward ray-tracing technique, and the total rendering time can be noticeably reduced. The method is suitable to create high quality integral image without the pseudoscopic problem. Real time and non-real time CGII rendering images and optical reconstruction are demonstrated, and the effectiveness is verified with different types of 3D object models. Real time optical reconstruction with 90 × 90 viewpoints and the frame rate above 40 fps for the CGII 3D display are realized without the pseudoscopic problem.
Collapse
|
32
|
Zhu X, Wang M, Xing S, Yang Z, Mao Y. 0348 The polymorphisms of Toll-like receptor 4 gene influences milk production traits in Chinese Holstein cows. J Anim Sci 2016. [DOI: 10.2527/jam2016-0348] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Gao YZ, Xing S, Gao K, Zhang JY, Yu ZZ, Shi XJ, Wang HW. [Posterior debridement combined with atlantoaxial fusion to upper cervical tuberculosis]. Zhonghua Wai Ke Za Zhi 2016; 54:451-455. [PMID: 27938580 DOI: 10.3760/cma.j.issn.0529-5815.2016.06.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore clinical results of posterior debridement combined with atlantoaxial fusion for upper cervical Tuberculosis. Methods: From March 2007 to April 2012, 8 patients with upper cervical Tuberculosis underwent posterior debridement combined with atlantoaxial fusion in our hospital were selected for retrospective analysis. 3 cases were males and 5 females, aged 29-65 (43.5±13.2) years. According to the pedicle destruction, using different screws (pedicle screw or laminar screw) fixation.In the preoperative and final follow-up, Japanese Orthopaedic Association score (JOA) and neck disability index (NDI) were used to evaluate neurological function and calculate improvement rate JOA score. At final follow-up, clinical efficacy was evaluated by Odom's grade. situation of internal fixation, fusion of upper cervical were assessed by imaging examination. During follow-up, complications were documented and analyzed. Results: Postoperatively 12 months, all bony fusion were achieved. Tuberculosis were reached clinical cure in 12-18 months. The JOA score increased from 10.5±2.0 preoperatively to 15.6 ±1.1 in final follow-up(P<0.05), and the NDI decreased from 29.9 ± 6.2 preoperatively to 8.6±1.6 (P<0.05). At last follow-up, according to Odom's standard, excellent were obtained in 6 cases (75.0%), good 1 cases (12.5%) and ordinary 1 case (12.5%). No severe complications was documented during follow-up. Conclusions: The treatment of posterior debridement combine with atlantoaxial fusion, and structure grafting and local anti-Tuberculosis drug using intraoperative, not only could obtain reliable clinical efficacy, completely removal of lesions, but also obtain strong stability, which plays an important role in the treatment of cervical tuberculosis.
Collapse
Affiliation(s)
- Y Z Gao
- Orthopaedic Department of the People's Hospital of Zhengzhou University (Henan Provincial People's Hospital) , Zhengzhou 450003, China
| | | | | | | | | | | | | |
Collapse
|
34
|
Gao YZ, Xing S, Gao K, Shi XG, Zhang JY, Yu ZZ, Kang YS. [Anterior retropharyngeal debridement combined with posterior atlantoaxial fusion for atlantoaxial Tuberculosis]. Zhonghua Yi Xue Za Zhi 2016; 96:1495-9. [PMID: 27266494 DOI: 10.3760/cma.j.issn.0376-2491.2016.19.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE To evaluate the clinical efficacy of anterior debridement combined with posterior atlantoaxial fusion for atlantoaxial Tuberculosis. METHODS From February 2005 to February 2013, 7 patients, 3 males and 4 females, with atlantoaxial Tuberculosis underwent anterior debridement combined with posterior atlantoaxial fusion in Department of Orthopedics Zhengzhou University People's Hospital were selected.In the preoperative and final follow-up, Japanese Orthopaedic Association score (JOA), neck disability index (NDI) and Frankel Classification were used to evaluate neurological function and calculate improvement rate.At final follow-up, clinical efficacy was evaluated by Odom's grade.Situation of internal fixation, fusion of upper cervical were assessed by X-ray, CT scan and MRI scan. RESULTS Bony fusion were achieved in 7 cases after operation in 12 months. Tuberculosis were reached clinical cure between 17 and 21 months. At follow The JOA score increased from (11.1±0.7) preoperatively to (15.3±0.5) in final follow-up(P<0.05), and the NDI decreased from (34.0±4.6) preoperatively to (10.1±1.3) in final follow-up (P<0.05). At last follow-up, according to Odom's standard, excellent were obtained in 5 cases, good 1 cases and ordinary 1 case. Frankel Classification of all cases improved from D class to E. CONCLUSIONS The treatment of anterior retropharyngeal debridement combine with atlantoaxial fusion, and local anti-tuberculosis drug using intraoperative, not only could obtain reliable clinical efficacy, completly removal of lesions, but also obtain strong stability, which plays an important role in the treatment of atlantoaxial Tuberculosis.
Collapse
Affiliation(s)
- Y Z Gao
- Department of Orthopedics, Henan Provincial People's Hospital (Zhengzhou University People's Hospital), Zhengzhou 450003, China
| | | | | | | | | | | | | |
Collapse
|
35
|
Vallieres M, Freeman C, Ahmed Z, Turcotte R, Hickeson M, Skamene S, Jeyaseelan K, Hathout L, Serban M, Xing S, Powell T, Seuntjens J, Levesque I, El Naqa I. Early Assessment of Tumor Aggressiveness Using Joint FDG-PET/MRI Textural Features: Prediction of Prospective Cohort and Potential Improvement Using Hypoxia and Perfusion Biomarkers. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
36
|
Liu G, Dang C, Peng K, Xie C, Chen H, Xing S, Chen X, Zeng J. Increased spontaneous neuronal activity in structurally damaged cortex is correlated with early motor recovery in patients with subcortical infarction. Eur J Neurol 2015; 22:1540-7. [PMID: 26453239 DOI: 10.1111/ene.12780] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2015] [Accepted: 06/05/2015] [Indexed: 11/26/2022]
Abstract
BACKGROUND AND PURPOSE Secondary cortical thinning and volumetric atrophy in the motor-related cortex can inhibit early functional recovery after subcortical infarction. However, the relationship between the spontaneous neuronal activity in these cortices and motor recovery in patients with focal cerebral infarct remains unknown. METHODS Structural magnetic resonance imaging (MRI) and resting-state functional MRI were conducted 1, 4 and 12 weeks after onset in 22 patients with an acute subcortical infarct and in 22 normal subjects. Group differences in cortical thickness and in the amplitude of low-frequency fluctuation (ALFF) in motor-related areas were evaluated, and the relationships between ALFF, cortical thickness changes and changes in the Fugl-Meyer scores of physical performance were further analyzed. RESULTS In patients with subcortical infarction, progressively decreasing cortical thickness was found over the observation period ipsilesionally in the primary motor cortex (PMC), supplementary motor cortex (SMC) and precuneus (all P < 0.05). Contralesionally, progressive increases in cortical thickness were detected in SMC and insula (all P < 0.05). Increases in ALFF were observed only in PMC (bilaterally) and only at 12 weeks after stroke (all P < 0.05). The cortical thickness changes in the contralesional SMC (rs = 0.483, P = 0.023) and the ALFF changes in bilateral PMC (ipsilesional, rs = 0.51, P = 0.015; contralesional, rs = 0.463, P = 0.03) were positively correlated with changes in the Fugl-Meyer scores. CONCLUSIONS These results suggest that increased spontaneous neuronal activity of the PMC, a region structurally damaged secondarily to ischaemic lesion, may contribute to early motor recovery in patients with subcortical infarction.
Collapse
Affiliation(s)
- G Liu
- Department of Neurology and Stroke Center, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - C Dang
- Department of Neurology and Stroke Center, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - K Peng
- State Key Laboratory of Oncology in Southern China, Imaging Diagnosis and Interventional Center, Cancer Center of Sun Yat-Sen University, Guangzhou, China
| | - C Xie
- State Key Laboratory of Oncology in Southern China, Imaging Diagnosis and Interventional Center, Cancer Center of Sun Yat-Sen University, Guangzhou, China
| | - H Chen
- Department of Neurology and Stroke Center, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - S Xing
- Department of Neurology and Stroke Center, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - X Chen
- Department of Neurology and Stroke Center, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - J Zeng
- Department of Neurology and Stroke Center, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| |
Collapse
|
37
|
Gong Z, Xing S, Zheng F, Xing Q. Increased expression of macrophage migration inhibitory factor in aorta of patients with coronary atherosclerosis. J Cardiovasc Surg (Torino) 2015; 56:631-637. [PMID: 24429801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM The aim of the present study was to investigate the changes of macrophage migration inhibitory factor (MIF) in the aorta of patients with coronary atherosclerosis and to evaluate the relationship between aortic expression levels of MIF and atherosclerotic risk factors. METHODS We collected discarded aortic specimens from patients (N.=36) undergoing coronary artery bypass graft surgery (CABG), and studied the presence and distribution of MIF by immunohistochemistry. The arterial tissues from 10 subjects without known atherosclerosis through the kidney donation program were taken as control group. The preoperative serum triglycerides, total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, lipoprotein(a), apolipoprotein A, apolipoprotein B, total bilirubin, direct bilirubin, and indirect bilirubin levels of patients were examined and the coronary angiography was performed in order to assess the severity of atherosclerotic lesions. RESULTS MIF was detectable in aorta from CABG patients. The aortic MIF expression was elevated in smokers, and patients with hypertension or diabetes. In addition, the aortic MIF expression was associated with the levels of triglycerides, total cholesterol, low density lipoprotein cholesterol, lipoprotein (a), apolipoprotein B, total bilirubin, direct bilirubin, indirect bilirubin and coronary severity scores in simple regression analysis. However, the expression of MIF was only correlated to coronary severity scores in multiple regression analysis. CONCLUSION MIF is overexpressed in aorta from patients with coronary atherosclerosis and the aortic MIF expression is correlated with the severity of coronary artery disease.
Collapse
Affiliation(s)
- Z Gong
- Department of Cardiology, Qianfoshan Hospital, Shandong University, Jinan, PR China -
| | | | | | | |
Collapse
|
38
|
Xing S, Wu H, Wang L, Wang J, Ye J. The expression of osteopontin in epithelium of keratocystic odontogenic tumor before and after marsupialization and decompression. Int J Oral Maxillofac Surg 2013. [DOI: 10.1016/j.ijom.2013.07.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Duan H, Luo Y, Hao H, Feng L, Zhang Y, Lu D, Xing S, Feng J, Yang D, Song L, Yan X. Soluble CD146 in cerebrospinal fluid of active multiple sclerosis. Neuroscience 2013; 235:16-26. [DOI: 10.1016/j.neuroscience.2013.01.020] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2012] [Revised: 12/20/2012] [Accepted: 01/02/2013] [Indexed: 11/28/2022]
|
40
|
Xing S, Jianrui Z. The effect of ischaemic precondition on acute myocardial infraction in patients less than 60 years. Heart 2011. [DOI: 10.1136/heartjnl-2011-300867.411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
41
|
Xing S, Wu Y, Wan L, Tao Z, Jiang H, Yuan Y. Evaluation of oro-mandibular-facial reconstruction using vascularized free fibular osteomyocutaneous flap. Int J Oral Maxillofac Surg 2011. [DOI: 10.1016/j.ijom.2011.07.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
42
|
Xing S, Zhen W. e0402 The expression and relation of the vitamin D3 up-regulated protein 1 in peripheral blood mononuclear cells from patients with coronary artery disease. Heart 2010. [DOI: 10.1136/hrt.2010.208967.402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Abstract
Glutaredoxins (GRXs) are small, ubiquitous oxidoreductases that have been intensively studied in E. COLI, yeast and humans. They are involved in a large variety of cellular processes and exert a crucial function in the response to oxidative stress. GRXs can reduce disulfides by way of conserved cysteines, located in conserved active site motifs. As in E. COLI, yeast, and humans, GRXs with active sites of the CPYC and CGFS type are also found in lower and higher plants, however, little has been known about their function. Surprisingly, 21 GRXs from ARABIDOPSIS THALIANA contain a novel, plant-specific CC type motif. Lately, information on the function of CC type GRXs and redox regulation, in general, is accumulating. This review focuses on recent findings indicating that GRXs, glutathione and redox regulation, in general, seem to be involved in different processes of development, so far, namely in the formation of the flower. Recent advances in EST and genome sequencing projects allowed searching for the presence of the three different types of the GRX subclasses in other evolutionary informative plant species. A comparison of the GRX subclass composition from PHYSCOMITRELLA, PINUS, ORYZA, POPULUS, and ARABIDOPSIS is presented. This analysis revealed that only two CC type GRXs exist in the bryophyte PHYSCOMITRELLA and that the CC type GRXs group expanded during the evolution of land plants. The existence of a large CC type subclass in angiosperms supports the assumption that their capability to modify target protein activity posttranslationally has been integrated into crucial plant specific processes involved in higher plant development.
Collapse
Affiliation(s)
- S Xing
- Max Planck Institute for Plant Breeding Research, Carl-von-Linné-Weg 10, 50829 Köln, Germany
| | | | | |
Collapse
|
44
|
Abstract
The Research Institute for Diagnosis and Treatment of Early Lung Cancer (RIDTELC) Lung Study was initiated to determine whether lung cancer screening by automated sputum cytometry combined with conventional sputum cytology and auto-fluorescence in addition to white light bronchoscopy could enhance the detection rate of early lung cancer. The present study analyses the initial findings to evaluate the efficiency of automated sputum cytology in predicting the diagnosis of lung cancer. In this study, malignancy grade was used as a predictive parameter for lung cancer. In total, 2,480 heavy smokers (>30 pack-yrs), aged 50-74 yrs, with no previous cancer in the last 5 yrs, received chest radiology, conventional sputum cytology and sputum cytometry screening. In total, twenty-seven lung cancers were diagnosed, representing a prevalence of 1.1%, 25 of which provided sputum samples. Positive automated sputum cytology results were seen in 176 smokers (7.2%), 10 (0.4%) of whom had severe dysplasia or higher lesions (positive results) by conventional sputum cytology examination. Out of 25 tumour cases, 20 had suspicious results using automated sputum cytology, representing 80% sensitivity. One patient out of 24 with tumours had positive results on conventional sputum cytology, representing a sensitivity of 4.2%. For all stages of squamous cell lung cancer and later stage adenocarcinoma the sensitivity of automated sputum cytology was 100%. For adenocarcinoma stage I sensitivity was 25%. In conclusion, DNA analysis of sputum slides by automated sputum cytology may be a suitable tool for the detection of early lung cancer and the characterisation of a high-risk group with pre-invasive lesions for follow-up.
Collapse
Affiliation(s)
- S Xing
- Research Institute for Diagnosis and Treatment of Early Lung Cancer, Augusta Teaching Hospital, Bergstr. 26, D-44971 Bochum, Germany
| | | | | | | | | | | |
Collapse
|
45
|
Abstract
Controversy remains regarding the ability of silicone materials to induce a specific immune reaction versus a nonspecific inflammatory response. Histopathological analysis of the tissue around failed breast implants reveals chronic inflammation with silicone gel droplets either surrounded by giant cells or engulfed by macrophages, areas of fibrosis, and necrosis. Macrophages are the key cells engulfing or forming foreign body giant cells. To address the mechanisms of silicone-induced inflammation a model of human monocyte-derived macrophages (MDMs) was developed. After sonication of silicone gel, the silicone droplets were embedded in Type I collagen and used to coat glass coverslips; human MDMs were subsequently seeded on the coverslips and maintained in culture for up to 7 days. The advantage of the model was that human macrophages could be studied histologically, and cytochemically as they interacted with well-characterized silicone materials. Initial analysis of the human macrophages shows phagocytosis of the silicone gel within hours of exposure to the material. Analysis for pro-inflammatory cytokines reveals significant transient secretion of IL-1 (p < 0.01) over controls by human macrophages upon exposure to silicone gel at 24 h.
Collapse
Affiliation(s)
- F Tavazzani
- Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada
| | | | | | | | | |
Collapse
|
46
|
Xing S, Santerre JP, Labow RS, Boynton EL. The effect of polyethylene particle phagocytosis on the viability of mature human macrophages. J Biomed Mater Res 2002; 61:619-27. [PMID: 12115452 DOI: 10.1002/jbm.10078] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Macrophages are the major cell type observed in the inflammatory membrane retrieved at implant revision surgery. In this study, mature human monocyte-derived macrophages (MDM) were adapted to a previously established in vitro model to examine the influence of high-density polyethylene (HDPE) particulate (4-10 microm) on MDM viability. HDPE particles were suspended in soluble type I collagen, which subsequently was solidified on glass coverslips. Mature human macrophages, derived from differentiating peripheral blood monocytes on polystyrene for 10 days, were incubated in culture media on collagen controls and collagen-particle substrata for 31 days. Histologic analysis demonstrated that MDMs were in contact with the particles at 2 h. The majority of the particles were associated with the cells within 24 h. Based on electron microscopy, those cells associated with the particles appeared to be morphologically activated rather than necrotic or apoptotic. Assessment of cell viability revealed no differences among the groups at 24 h, but at 31 days significantly more viable cells and higher DNA values were found associated with the particle groups versus the collagen controls. The histologic results validate human mature MDMs as a clinically relevant cell type for study of the role of polyethylene particulate in aseptic loosening. The cell viability results indicate that phagocytosis of HDPE is not toxic to MDMs but in fact prolongs MDM survival. The long-lived MDMs may play a role in perpetuating chronic inflammation surrounding implants.
Collapse
Affiliation(s)
- S Xing
- Institute of Biomaterials and Biomedical Engineering, University of Toronto, 170 College Street, Toronto, Ontario, Canada M5S 3E3
| | | | | | | |
Collapse
|
47
|
Xing S, Santerre JP, Labow RS, Boynton EL. Differential response to chemically altered polyethylene by activated mature human monocyte-derived macrophages. Biomaterials 2002; 23:3595-602. [PMID: 12109684 DOI: 10.1016/s0142-9612(02)00088-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Macrophages and polyethylene (PE) particulate are currently recognized as being the two common denominators in the development of chronic inflammation, periprosthetic osteolysis, and subsequent implant failure. In this study, the effect of PE particulate surface chemistry on mature human monocyte-derived macrophage (MDM) function was investigated. Virgin high-density PE (HDPE: 4-10 microm) and HDPE oxidized by irradiation, thermal and chemical treatment were characterized by FT-IR and suspended in soluble type I collagen, which was subsequently solidified on glass coverslips. Human MDMs, derived from differentiating monocytes on polystyrene for 14 days, were trypsinized and cultured on collagen-particle substrata and collagen controls for 31 days. Analysis of conditioned media collected at 24h incubation showed a significantly higher level of IL-1beta secretion in virgin HDPE over oxidized HDPE or collagen controls, and a significant inhibition of IL-6 secretion in both virgin and oxidized samples. Esterase activity was increased in the medium at a significantly higher level in the virgin HDPE versus controls with the highest activity observed in oxidized HDPE at 31 days. These results illustrate the effect of PE particle surface chemistry (oxidation) on MDM cytokine secretion and esterase activity, and highlight the need to further investigate the potential of PE surface chemistry on modulating MDM function.
Collapse
Affiliation(s)
- S Xing
- Institute of Biomaterials and Biomedical Engineering, University of Toronto, Canada
| | | | | | | |
Collapse
|
48
|
Xing S, Yuan L, Song R, Xu F. [Analysis on the dermal irritation caused by imported cosmetics]. Wei Sheng Yan Jiu 2001; 30:371-3. [PMID: 12561625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
Dermal irritation tests on 902 kinds of cosmetics were conducted. The acute dermal irritation/corrosion tests for 175 samples showed no irritation in 65.1% of them, and 34.9% of them were considered as slight irritation. The chronic dermal irritation/corrosion tests for another 727 samples showed no irritation for 32.2% of them, and 67.8% of them were considered as slight irritation, most of which are lipsticks, eye shadows, fluid powder foundations and powder foundations.
Collapse
Affiliation(s)
- S Xing
- Institute of Environmental Health Monitoring, Chinese Academy of Preventive Medicine, Beijing 100021, China
| | | | | | | |
Collapse
|
49
|
Wang Y, Xing S, Dong X. [Effect of hormone replacement therapy on hemorheology in postmenopausal women]. Zhonghua Fu Chan Ke Za Zhi 2001; 36:476-8. [PMID: 11758183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
OBJECTIVE Our study is to observe the effects of conjugated equine estrogen (CEE) combined with medroxyprogesterone acetate (MPA) on hemorheology in postmenopausal women in order to evaluate mechanism responsible for the increase in the incidence of cardiovascular disease after menopause and also to provide proper instruction and advice of hormone replacement therapy (HRT) for postmenopausal women. METHODS 60 healthy postmenopausal women were assigned to 3 groups randomly, 20 cases in each group. Group A: CEE 0.625 mg/d + MPA 2 mg/d + calcium carbonate co. (Ca-D) 600 mg/d. Group B: CEE 0.3 mg/d + MPA 2 mg/d + Ca-D 600 mg/d. Group C: Ca-D 600 mg/d only served as control. Measurements of hemorheological parameters were performed before and 6 months after treatment. RESULTS After 6 months of HRT, group A: blood viscosity under the shear rate of 94.5 s-1 dropped from (5.23 +/- 0.37) mPa.s to (5.03 +/- 0.43) mPa.s (P < 0.05), plasma viscosity dropped from (1.66 +/- 0.19) mPa.s to (1.58 +/- 0.15) mPa.s (P < 0.05), erythrocyte deformability dropped from (4.76 +/- 0.32) mPa.s to (4.54 +/- 0.34) mPa.s (P < 0.05). Group B: blood viscosity under the shear rate of 94.5 s-1 dropped from (5.10 +/- 0.30) mPa.s to (4.87 +/- 0.30) mPa.s (P < 0.05), erythrocyte deformability dropped from (4.65 +/- 0.34) mPa.s to (4.43 +/- 0.29) mPa.s (P < 0.05). No change was found in the control group. After treatment, the levels of plasma viscosity and fibrinogen in group A were much lower than that in group C (P < 0.05). The whole blood viscosity and plasma viscosity in group B were much lower than that in group C (P < 0.05). Thrombelastogram study demonstrated no change regardless HRT or not (P > 0.05). CONCLUSION Both different dosages of CEE have favor effects on blood viscosity and erythrocyte deformabillity, which could play the role in preventing cardiovascular disease in postmenopausal women.
Collapse
Affiliation(s)
- Y Wang
- Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing 100029, China
| | | | | |
Collapse
|
50
|
Hou Q, Xing S. [The national symposium on pregnancy induced hypertension]. Zhonghua Fu Chan Ke Za Zhi 2001; 36:199-201. [PMID: 11783359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
|